Atara Biotherapeutics
ATRA
35 hedge funds and large institutions have $19.6M invested in Atara Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 16 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
15.29% less ownership
Funds ownership: 57.88% → 42.58% (-15%)
18% less capital invested
Capital invested by funds: $24.1M → $19.6M (-$4.44M)
27% less funds holding
Funds holding: 48 → 35 (-13)
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$533K |
| 2 |
Millennium Management
New York
|
+$509K |
| 3 |
Renaissance Technologies
New York
|
+$186K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$151K |
| 5 |
VPC
Vestal Point Capital
New York
|
+$109K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$1.41M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$873K |
| 3 |
CC
Centiva Capital
New York
|
-$829K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$603K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$314K |
ATRA Hedge Fund Activity: Q3 2024 in Review
35 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q3 2024, worth a combined $19.6M — down 18% from $24.1M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ATRA and 3 opened new positions — a net loss of 13 holders — while 12 trimmed existing stakes and 13 added.
The largest buyer was EcoR1 Capital, adding an estimated $533K. The largest seller was Boxer Capital, exiting entirely with an estimated $1.41M sold.
- 35 institutional investors held Atara Biotherapeutics (ATRA) as of Q3 2024, down from 48 in Q2 2024.
- Funds reported $19.6M of Atara Biotherapeutics stock for Q3 2024, down 18% quarter-over-quarter.
- 3 funds opened new Atara Biotherapeutics positions in Q3 2024 and 16 closed out, a net change of -13 holders.
- The largest Atara Biotherapeutics buyer in Q3 2024 was EcoR1 Capital, an estimated $533K added.
- The largest Atara Biotherapeutics seller in Q3 2024 was Boxer Capital, an estimated $1.41M sold.
Based on aggregated 13F filings for Q3 2024.